(Q44244716)

1 December 2017

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes (English)

1 reference

1 December 2017

1 reference

1

Josephine M Egan

1 reference

1 December 2017

Graydon S Meneilly

2

1 reference

PubMed ID

12475750

1 December 2017

Dariush Elahi

series ordinal

3

1 reference

1 December 2017

10 December 2002

1 reference

American Journal of Physiology - Endocrinology and Metabolism

1 December 2017

1 reference

1 December 2017

284

1 reference

1 December 2017

6

1 reference

1 December 2017

E1072-9

1 reference

1 December 2017

Glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Minireview: the glucagon-like peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

On the determination of basal glucose production rate in patients with type 2 (non-insulin-dependent) diabetes mellitus using primed-continuous 3-3H-glucose infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Insulin control of glucose metabolism in man: a new kinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Sequential hyperglycemic-euglycemic clamp to assess beta-cell and peripheral tissue: studies in female athletes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00315.2002

10.1152/AJPENDO.00315.2002

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference

PubMed ID

12475750